[
    "{\"step_by_step_thinking\": \"The patient has ankylosing spondylitis that is not responding to conventional nonsteroidal anti-inflammatory drugs or sulfasalazine. According to Document [1], infliximab, a tumor necrosis factor \u03b1 (TNF\u03b1) inhibitor, has been shown to improve symptoms in patients with ankylosing spondylitis who are refractory to conventional treatment. Document [18] also mentions that anti-TNF\u03b1 therapy with infliximab and etanercept has shown to be highly effective in patients with ankylosing spondylitis resistant to conventional therapy. Therefore, the next step in treatment should be administration of a drug that inhibits TNF\u03b1.\", \"answer_choice\": \"D. Tumor necrosis factor \u03b1\"}"
]